Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Prabakaran, Mookkan ^a   Prabhu, Nayana ^a   He, Fang ^a   Hongliang, Qian ^a   Ho, Hui Ting ^a   Qiang, Jia ^a   Meng, Tao ^a   Goutama, Michael ^b   Kwang, Jimmy ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Tridel Biosciences International Pte Ltd   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2D9; MONOCLONAL ANTIBODY 4C2; UNCLASSIFIED DRUG; HYBRID PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; LETHAL DOSE; MONOTHERAPY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS STRAIN; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; CELL LINE; DOG; DOSE RESPONSE; DRUG COMBINATION; GENETIC REASSORTMENT; GENETICS; HUMAN; LUNG; MUTATION; ORTHOMYXOVIRUS INFECTION; PASSIVE IMMUNIZATION; PATHOLOGY; PHYSIOLOGY; SERODIAGNOSIS; VIROLOGY;

INFLUENZA A VIRUS; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H5N1 SUBTYPE; LUNG; MICE; MUTATION; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; RECOMBINANT FUSION PROTEINS;

EID: 66249098565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005672     Document Type: Article

References (33)

1. Veits J, Romer-Oberdorfer A, Helferich D, Durban M, Suezer Y, et al. (2008) Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26: 1688-1696.
2. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, et al. (2004) Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430: 209-213.
3. de Jong MD, Hien TT (2006) Avian influenza A (H5N1)-Review. J Clin Virol 35: 2-13.
4. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437: 1108.
5. Casadevall A, Dadachova E, Pirofski L (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2: 695-703.
6. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Eng J Med 357: 1450-1451.
7. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: Convalescent blood products for Spanish Influenza Pneumonia: A future H5N1 treatment? Ann Intern Med 145: 599-609.
8. Lu J, Guo Z, Pan X, Wang G, Zhang D, et al. (2006) Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice. Respir Res 7: 43.
9. Prabhu N, Prabakaran M, Ho H, Velumani S, Qiang J, et al. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A H5N1 infection. J Virol 83: 2553-2562.
10. Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response multiple injections of murine monoclonal IgG. J Immunol 135: 1530-1535.
11. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza H5 hemagglutinin in mice. Respir Res 7: 126.
12. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PloS Med 4: e178.
13. Bakker ABH, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79: 9062-9068.
14. de Kruif J, Bakker ABH, Maissen WE, Kramer RA, Throsby M, et al. (2007) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58: 359-368.
15. Prabakaran M, Ho HT, Prabhu N, Velumani S, Szyporta M, et al. (2009) Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS ONE 4: e4566.
16. He Q, Velumani S, Du Q, Lim CW, Ng FK, et al. (2007) Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin Vaccine Immunol 14: 617-623.
17. Anonymous (1995) Laboratory biosafety manual. World Health Organization. Ann Ist Super Sanita 31: 1-121.
18. Centers for Disease Control and Prevention (U.S.), and National Institutes of Health (U.S.) (1999) Biosafety in microbiological and biomedical laboratories, 4th ed. Washington [Bethesda, Md.].Washington, D.C.: U.S. Dept. of Health and Human Services Public Health Service Centers for Disease Control and Prevention; National Institutes of Health; For sale by the Supt. of Docs. U.S. G.P.O.
19. World Health Organization (2004) Laboratory biosafety manual, 3rd ed. Geneva: World Health Organization.
20. Yokoyama WM (2004) Production of monoclonal antibody., Current Protocols in Immunology, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Newcastle, United Kingdom: John Wiley & Sons. Inc. pp 2.5.1-2.5.17.
21. Velumani S, Du Q, Fenner BJ, Prabakaran M, Wee LC, et al. (2008) Development of an antigen-capture ELISA for detection of H7 subtype avian influenza from experimentally infected chickens. J Virol Methods 147: 219-225.
22. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E (1991) Efficacy of nucleoprotein and hemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9: 303-308.
23. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, et al. (2007) Structure of antigenic sites on the hemagglutinin molecule of H5 influenza virus and phenotypic variation of escape mutants. J Gen Virol 83: 2497-2505.
24. Jostock T, Vanhove M, Brepoels E, van Gool R, Daukandt M, et al. (2004) Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 289: 65-80.
25. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, et al. (2008) Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and 376 recombinant CTB as an adjuvant. Virology 380: 412-420.
26. Suguitan Jr, Mc Auliffe ALJ, Milis KL, Jin H, Duke G, et al. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross protection in mice and ferrets. PLoS Med 3: e360.
27. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
28. +by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 72: 3235-3240.
29. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, et al. (2001) Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75: 12198-12208.
30. Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, et al. (2006) Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80: 2654-2664.
31. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47: 57-77.
32. Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM (2002) Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 20: 1956-1960.
33. Meulen JT, van den Brink EN, Poon LLM, Marissen WE, Leung CSW, et al. (2006) Human monoclonal antibody combination against SARS coronovirus: Synergy and coverage of escape mutants. PLoS Med 3: e237.